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Abstract 
One of the DNA repair machineries is activated by Poly (ADP-ribose) Polymerase (PARP) enzyme. 
Particularly, this enzyme is involved in repair of damages to single-strand DNA, thus decreasing the 
chances of generating double-strand breaks in the genome. Therefore, the concept to block PARP 
enzymes by PARP inhibitor (PARPi) was appreciated in cancer treatment. PARPi has been designed 
and tested for many years and became a potential supplement for the conventional chemotherapy. 
However, increasing evidence indicates the appearance of the resistance to this treatment. 
Specifically, cancer cells may acquire new mutations or events that overcome the positive effect of 
these drugs. This paper describes several molecular mechanisms of PARPi resistance which were 
reported most recently, and summarizes some strategies to reverse this type of drug resistance. 
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Introduction 
Poly (ADP-ribose) polymerases (PARPs) 
comprise an extended superfamily of seventeen 
proteins with different cellular functions including 
spindle pole formation, cell cycle regulation, cell 
death, inflammation, adaptive immunity, and DNA 
repair [1]. More importantly, PARPs are well 
characterized for the crucial function in DNA breaks 
repair. For example, PARP1 repairs single-strand 
breaks (SSBs) through Base Excision Repair (BER) 
pathway [2]. In this process, PARP1 binds to the site 
of SSB taking part in synthesis of Poly (ADP-ribose) 
polymer molecules (PARs) from NAD+ and 
ADP-ribose molecules [3]. Notably, these polymers 
contain a big negative charge which increases the 
electrostatic repulsion between the negative 
phosphate groups allowing the tight chromatin 
organization to get looser and recruit other BER 
proteins such as DNA glycosylases, DNA 
polymerases, and DNA ligases [4, 5].  
Over the past few decades, PARP1 enzyme 
gained attractions as a promising target for 
chemotherapeutics. PARP inhibition results in a 
significant amount of double-strand breaks (DSBs) 
through the mechanism of interfering with replication 
fork at the site of DNA damage [2-4]. For this reason, 
PARP inhibitors (PARPi) can target those cells with 
impaired DNA DSB repair related to homologous 
recombination (HR) [2-4]. Researchers propose that 
inhibition of PARP1 could be enhanced further by 
applying a synthetic lethal concept [6]. This concept 
states that two mutations occurring within either 
tumor suppressors or proto-oncogenes might lead to 
cell death, whereas a single mutation within just one 
of two genes appears to be less dramatic [6]. An 
example of synthetic lethal concept related to PARP 
inhibitors is observed in cells with defected BRCA1 
and BRCA2. The clinical trials of PARPi show great 
promising underway in ovarian cancer [7]. For 
instance, in Phase I and II clinical trials Pfizer and 
AstraZeneca pharmaceutical companies tested effects 
of AG014699, PF01367338, Olaparib, and AZD2281 
PARP1 inhibitors in breast cancer with mutations in 
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BRCA genes [4, 8]. Despite the promising preliminary 
results, a prolonged treatment of cancer with PARP 
inhibitors is frequently associated with resistance to 
this therapy. For example, it has been shown that 
BRCA2 gene with secondary mutations shows drug 
resistance to cisplatin and PARPi [9, 10]. Therefore, 
many ongoing studies aim to understand the 
fundamentals as well as details of this phenomenon in 
order to increase the efficiency of the PARPi therapy. 
This review article will discuss the updated novel 
mechanisms of resistance to PARP chemotherapy and 
different strategies to reverse the evasion of the PARPi 
drugs.  
Molecular Mechanisms Underlying the 
Resistance to PARP inhibitors 
Even though approaches to treat some types of 
cancer have been improved in recent years, majority 
of patients are treated with standardized therapies, 
which usually underestimate the unique features of 
relapsed tumors [11]. Alternatively, targeted therapies 
provide the more efficient strategy. One of the good 
examples of targeted therapies is inhibition of PARP 
enzymes in certain types of tumor characterized by 
deficiency in homologous recombination pathway in 
DNA repair process [12]. However, like many 
treatments, tumors frequently acquire resistance to 
PARP inhibitors. As drugs targeting PARP enzymes 
become more widespread, the problem of resistance 
remains more significant and alarming [2]. 
Consequently, to make chemotherapy more effective, 
careful study and analysis of details of molecular 
mechanisms leading to tolerance of PARP inhibitors is 
very important.  
One of the popular PARPi drug, Olaparib, has 
shown its effectiveness in ovarian, breast, prostate, 
and pancreatic cancers [13]. Researchers designed 
PARP-inhibitor-resistant (PIR) cells to study PARP 
inhibitor resistance mechanisms in more details [14]. 
Multiple approaches have been used to identify the 
kinetic property of PAPRi such as RNA inference 
(RNAi) screening, genome editing, knockin mouse 
models to understand the resistance mechanisms [15]. 
Comprehensive study of these molecules would make 
PARPi resistance mechanism clearer and meaningful 
which should definitely increase the efficacy of PARPi 
[16]. Studies on mechanisms of resistance to PARPi 
derive largely from cell culture, animal, and patient 
models. One example comes from an in vivo model 
where it is observed that cancer cells treated with 
Olaparib drug develop resistance via partial 
restoration of homologous recombination molecular 
pathway [17]. On molecular level, resistance to PARPi 
is often related to the concept of synthetic lethality 
[18]. The principles of synthetic lethality explain well 
the drug resistance problem. For example, BRCA 
genes and PARP gene could be thought as a synthetic 
lethal pair [19]. PARPi resistance caused by secondary 
mutation in BRCA genes emerged by a synthetic 
lethal interaction between those molecules [20]. 
Followings are details of the previous and updated 
findings of molecular pathways contributed to the 
PARPi resistance.  
Resistance by new BRCA1 Deletion Isoforms: 
Rdd-BRCA1/RING-less BRCA1) and exon11 
deletion splice variant 
BRCA1 is a predisposed marker for breast cancer 
if mutated. BRCA1 has multiple functions in cell cycle 
arrest, cell proliferation, HR mediated DSB repair and 
Ubiquitination as an RING type of E3 ligase [21]. Full 
length BRCA1 contains N-terminal RING domain, 
coiled-coil domain and C-terminal domains (BRCT) 
[21]. Through coil domain, BRCA1 forms a complex 
with BRCA2-RAD51 for DSB repair. Through BRCT 
domain, BRCA1 can bind phosphorylated proteins 
such as C-terminal 1 interaction protein 1(CtIP) [21]. 
BRCA1-associated RING domain 1 (BARD1) is a 
binding partner for stabilization of BRCA1 and the E3 
ligase activity [21]. It has been found that BRCA1 
truncated forms play essential roles in PARPi 
resistance. BRCT domain deletion mutant maintains 
integrity of RAD51 binding region for DNA repair as 
a mechanism of PARPi resistance [22]. Moreover, 
single amino acid mutation at RING domain C61G not 
only disrupts the BRCA1 function as a tumor 
suppressor but also gains a function of promoting the 
PARPi resistance and decreases the sensitivity of 
cancer cells to DNA damage drug platinum [23]. 
However, another RING domain mutation of I26A 
does not abolish the binding ability to BARD1, tumor 
suppressing and E3 ligase activity [24].  
Two similar new discoveries just published 
while we were revising this review manuscript. One 
study showed that novel RBCA1 deletion forms can 
mediate PARPi resistance including 
RING-domain-deficient BRCA1 (Rdd-BRCA1) and 
different variants [25-27]. Both of the two studies used 
SUM1315MO2 cell line which was developed from a 
skin metastasis of ductal carcinoma [25]. 
SUM1315MO2 cells harbor the BRCA1185delAG allele 
[25]. One study applied drug resistant cells generated 
from continuing PARPi Rucaparib/cisplatin 
treatment [26]. The authors found that acquired 
PARPi resistance was not induced by secondary lethal 
mutation but by N-terminal RING domain deletion of 
Rdd-BRCA1 [26]. Further analysis identified the 
translation start amino acid is Met-297 but not others 
due to favor of the RNA secondary structure [26]. 
Functionally, Rdd-BRCA1, independent on BARD1, 
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induces PARPi resistance both in cell lines and 
xenograft model. Rdd-BRCA1 also expressed in 
ovarian carcinomas patient samples [26]. Another 
similar study also used engineering mice with 
conditional knockout of wild type of BRCA1 but 
harbor Brca1185delAG alleles in epithelium with the 
secondary p53 knockout cancer model [27]. 
BRCA1185delAG mutation generates only 11 amino acid 
early stop of translation of BRCA1 protein and results 
in loss of RING domain [25]. It has been shown in this 
study that a new gene named RING-less Brca1 highly 
expresses in knockout Brca1185delAG allele. A man-made 
early stop mutation of Brca1185stop generated in this 
study showed high resistance to the PARPi in mouse 
model [27]. Further analysis in human breast cancer 
cell line SUM1315MO2 identified a protein band of 
loss of RING domain of BRCA1 [27]. Brca1 formed 
foci with Rad51 upon γ irradiation in cells generated 
from Brca1185stop mouse mammary tumors but not in 
wild type BRCA1 controls [27]. Thus clinical relevant 
mutation of BRCA1185delAG mediates drug resistance to 
PARPi [27]. Therefore, RING domain plays essential 
roles in prevention of drug resistance. However, how 
RING domain can exert the drug sensitization and 
through which signaling pathways are largely 
unknown. As RING domain plays essential roles in E3 
ligase activity, ubiquitin system might fine tune the 
drug sensitivity through inhibition of HR mediated 
DSB repair. In addition, BRCA1-Δ11q is a deletion of 
almost whole exon 11 as a splice variant. Using 
CRISPR/Cas9 genome editing mediated 
downregulation studies the authors found that 
BRCA1-Δ11q protein can mediate PARPi resistance 
with DNA damage drug cisplatin in a mouse model 
[28]. However, the detailed mechanisms are unclear.  
Resistance by Epigenetic Re-expression of 
BRCA1  
Given that BRCA1 is essential to PARPi 
sensitivity; epigenetic re-expression of BRCA1 may 
confer the drug resistance to PARPi. The most recent 
report published just while we were writing this 
paper showed the epigenetic resistance of PARPi 
through BRCA1 using a precision oncology approach 
of patient-derived xenograft (PDX) models [29]. These 
mice developed PARPi Olaparib drug resistance in 
83% of 18 mice treated with Olaparib [29]. Further 
studies showed that 73% of drug resistant PDX 
tumors were BRCA1 positive due to re-expression of 
BRCA1 by loss of methylation in BRCA1 promoter 
detected in 70% of 23 resistant tumors [29]. Detected 
RAD51 foci, BRCA1 gene fusions and target locus 
amplification in those drug resistant tumors suggest 
that the HR mediated genome arrangement may 
re-activate BRCA1 transcription through epigenetic 
regulation for PARPi drug resistance [29].  
Replication Fork Stabilization  
Another novel mechanisms reported just while 
we were writing the manuscript is that replication 
machinery stabilization contributes to drug resistance. 
In details, a DNA damage response protein, Pax2 
transactivation domain-interacting protein (PTIP) 
which can form nuclear foci for DSB of DNA, can 
destabilize MRE11 nuclease in stalled replication 
forks [30]. Thus PTIP defective can stabilize nascent 
DNA strands by prohibiting degradation. This 
mechanism is found in BRCA1/2 deficient cells and 
contributes to PARPi and cisplatin resistance [30]. 
Recently, another report consistently found the same 
mechanism of PARPi resistance that similar to PTIP, 
PARP one allele loss can prohibit recruiting Mre11 
nuclease to the stalled replication forks in Brca2 null 
mice [31]. Thus PARPi Olaparib can overcome drug 
resistance in BRCA2-deficient cells [31]. However, 
loss of PTIP or PARP does not restore HR pathways 
[30, 31].  
Intragenic Deletion and Genetic Reversion of 
BRCA1/2 
 Some PARP-resistant cell lines often possess a 
deletion within the BRCA2 gene [14]. A second 
mutation might restore an open reading frame (ORF) 
of the mutant BRCA2 [14, 32]. One study showed that 
intragenic deletion of the c.6174delT caused 
restoration of the ORF that led to the synthesis of new 
isoforms of BRCA2 which most likely contributed to 
the restoration of DNA repair through HR [14]. Thus 
the reverse mutations in defective BRCA1 and BRCA2 
genes contribute to resistance for HR–deficiency 
therapy. Some secondary mutations could correct the 
original violation and by that means make tumors 
resistant to treatments and increased the competence 
to HR to some extent [33]. For example, Sakai and 
coworkers observed secondary mutations within the 
BRCA2 gene that restored ORF allowing the 
HCC1428, BRCA2-defective cells to be resistant to 
PARPi drugs [33]. 
Regulation by microRNA  
MicroRNA (miRNA) is a type of non-coding 
RNA which inhibits expression of target genes 
contributing to activation or repression of signaling 
pathways in cancer cells. Recently Choi and his 
coworkers identified that expression of miR-622 
mediated PARPi resistance through suppression of 
non-homologous end joining pathway (NHEJ). Based 
on results, overexpression of miR-622 is associated 
with decreased expression of genes such as 53BP1, 
Ku70, and Ku80 [34]. However, miR-622 induces 
PARPi resistance by directly targeting mRNAs of 
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Ku70 and Ku80 but not 53BP1 in BRCA1-mutant 
ovarian cells [34]. The researchers revealed that this 
miRNA blocked the conventional NHEJ pathway that 
leads to activation of HR repair mechanism by 
accumulation of Mre11 foci at the sites of DSBs [34]. 
Thus, miR-622 elevation may limit NHEJ and promote 
the HR pathway by balancing between NHEJ and 
DSB repair pathways which mediates resistance to 
PARPi. Moreover, other studies showed that miR-96, 
miR-107 miR-222 suppress DNA repair protein, 
RAD51 mRNA thereby disrupting DSB repair 
mediated through HR [35]. In addition, RNAi 
mediated library screening with PARP inhibitors 
identified that miR-182 is a miRNA that directly 
inhibits BRCA1 transcript [36]. In a xenograft model 
with injection of miR-182 overexpressing breast 
cancer MDA-MB-231 cells, the tumor growth was 
decreased upon 10 days treatment with PARPi of 
Olaparib [36]. Researchers further showed that 
miR-182 deceases HR efficiency and promotes cell 
sensitivity to DNA damage induced by radiation or 
chemical compound [36].  
Phosphorylation of PARP1 by c-Met  
Several pre-clinical studies report that 
proto-oncogene c-Met contributes to PARP inhibitor 
resistance in triple-negative breast cancer (TNBC) 
cells [37]. However, c-Met is overexpressed in 
different cancers including but not limited to ovarian, 
breast, bladder, and colorectal and usually associated 
with poor prognosis [38]. Furthermore, cells with 
overexpression of c-Met show high resistance to 
PARP inhibitors [37]. On the contrary, cell lines with 
knockdown of c-Met tend to be more responsive to 
inhibition of PARP enzymes [37]. Specifically, Duo 
and his coworkers found that c-Met phosphorylates 
PARP1 at Tyr907 site in different TNBC cell lines 
including HCC1937, MDA-MB-157, and 
MDA-MB-453. Phosphorylated PARP at Tyr907 
shows higher enzyme activity and lower binding 
activity to PARPi than that of non-phosphorylated 
PARP, which promotes tumor cells to develop PARPi 
resistance [37]. Overall, the researchers proposed that 
patients with TNBC, who was positive for 
pY907-PARP1 and c-Met, tend to be at greater risk for 
developing resistance to PARP inhibitors [37].  
Overexpression of HOX Family  
HOX gene family members are master regulators 
of organism development including embryo and axis 
in animals. Recently Esposito and her colleagues 
demonstrated that HOX proteins play a role in 
resistance to PARP inhibitors [39]. The researchers 
found that different HOXs participate in DNA repair 
process. For example, HOXB9 activated TGF-β 
signaling pathway that may recruit ATM to the sites 
of DSBs in cells lines from breast tumors [39]. They 
studied the role of HOXA9 in resistance to PARPi in 
PARPi-sensitive AML1-ETO and PML-RARα- 
transformed cell lines by overexpressing HOXA9 [39]. 
Specifically, AML1-ETO and PML-RARα are two 
transcription factors expressed in acute myeloid 
leukemia (AML) [39]. Importantly, these two fusion 
oncoproteins appear to be very sensitive for PARPi 
[39]. According to the results, higher levels HOXA9 
lead to more RAD51 being accumulated at the foci 
formation during HR repair in cancer cells [39].  
Overview of Mechanisms from Previous 
Reviews: drug transporters, mTOR, cell 
inflammation pathways, PARP itself and loss of 
53BP1 
Usually drug efflux machinery plays essential 
roles in directly resisting the action of drugs. ATP 
binding cassette (ABC) transporter family is a large 
family of drug efflux pump. For example, one 
member of ABC family, P-glycoprotein (Pgp) 
transports cellular molecules, nutrients, drugs, and 
toxins. Pgp is encoded by ABCB1 (also known as 
MDR1) gene, which is found to be upregulated in 
some cancer cells having resistance to chemotherapy 
[40]. The resistance to Olaparib is associated with 
increased expression of the ABC genes [41-45]. The 
resistance can be reversed by applying Pgp inhibitor 
Tariquidar combined with PARPi, AZD2281 [42]. 
Thus, non-Pgp-substrate type of PARPi is more 
promising in effective treatment such as Veliparib and 
CEO-8983 [43]. Researchers also found EMT 
contributes to Pgp induced PARPi resistance [45]. 
Furthermore, it is still under investigation whether 
overexpression of Pgp is the main resistance 
mechanism apart from BRCA1 gene restoration and 
loss of 53BP1 [46]. In addition, mTOR pathway 
contributes to resistance to PARPi. Specifically, 
phosphorylating S6 ribosomal protein would lead to 
PARPi resistance in BRCA1-deficient cancer cell lines 
[47]. Substitutive mutation of S6 ribosomal protein of 
all five phosphor-sites including S235, S236, S240, 
S244, and S247 could restore sensitivity of tumor cells 
to PARPi via inhibition of S6 phosphorylation [47]. 
Mechanistically, S6 phosphorylation causes PARPi 
resistance by activating mTOR pathway and restoring 
HR in BRCA-deficient cancer cells [47-48]. Changes in 
PARP1 expression levels in cancer cells also lead to 
resistance to PARPi. Elevation of PARP1 mediates 
resistance to PARPi in BRCA1-deficient HCC1937 
cells and is related to worse outcomes in patients with 
breast cancer [49-52]. Cell inflammatory pathways 
also may contribute to drug resistance of PARPi [53]. 
Particularly, Knockdown or inhibition of NF-κB 
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signaling component restored sensitivity to PARP 
inhibitors [53-55]. Moreover, 53BP1 loss which 
partially recovered HR was observed in some PARP 
resistant cancer cells through competitive binding to 
the repair machinery complex [56-58]. Based on 
previous reviews, molecular mechanisms associated 
with resistance to PARPi can be found in more 
literatures [59-66].  
Strategies of Overcoming PARPi Drug 
Resistance 
Mild Hyperthermia 
One of the promising solutions to deal with the 
issue of inefficiency of long-term application of PARP 
inhibitors in tumor cells is hyperthermia. 
Hyperthermia has been widely used solely or in 
combination with other methods for cancer treatment 
[67]. Hyperthermia acts on cancer cells in several 
pathways. For example, elevation of body 
temperature causes membrane damage, protein 
denaturation, inhibition of cell proliferation and DNA 
repair [69-72]. All of these effects lead to cell death by 
either apoptosis or necrosis [69-72]. In addition, 
hyperthermia activates anti-tumor immune signaling 
[69]. Mild hyperthermia has been used to overcome 
resistance to PARP inhibition. In the experiment of the 
effects of hyperthermia and PARP inhibitors on mice 
carrying BRO-derived tumors, the elevation in 
temperature or treatment with PARPi, PJ-34 or 
Olaparib alone did not decrease tumor growth but the 
combination with hyperthermia significantly 
inhibited tumor growth [73]. 
Hyperthermia promotes cancer cells to be 
sensitive to PARP inhibitors by inducing synthetic 
lethality [73]. Normally, cells use HR repair pathway 
for DSBs. It has been shown that HR starts from 
formation of a protein complex at DNA repair foci; 
this complex is made up three interacting proteins 
including Mre11, Rad51, and NBS1 [74]. This complex 
acts as an exonuclease creating 3’ overhangs at the 
both sites of breakage that stabilized by replication 
protein A (RPA) protein [74]. Then, RAD51 mediates 
strand invasion process by binding to the 3’ 
overhangs displacing the RPA protein from them and 
finding complementarity between the invading strand 
and homologous chromosome [74]. However, cells, 
which are exposed to high temperatures, cannot rely 
on HR pathway [75]. Specifically, HR inhibition is 
mediated by several mechanisms, including 
inactivation of RPA, degradation of BRCA1 and 
BRCA2, and decrease in MRE11 gene expression [73]. 
More importantly, when HR is not activated DSBs get 
accumulated which usually can lead to apoptosis [73]. 
Despite its positive effects on sensitizing tumors 
to PARP inhibition, cells can develop thermotolerance 
[76]. This thermotolerance can be caused by 
heat-shock response [67]. The latter is mediated by 
heat-shock proteins (HSPs). One of the major players 
in this response is HSP90. Researchers try to inhibit 
this protein to minimize its effect on thermotolerance. 
Krawczyk and colleagues highlight that the 
combination of mild hyperthermia, Olaparib, and 
HSP90 inhibitor, 17-(dimethylaminoethylamino)-17- 
demthoxygeldanamycin (17-DMAG) led to a 
complete loss of tumor growth [73]. For instance, all of 
the mice treated with this combination survived 
during the course of the treatment. On the contrary, 
survival of mice received treatment of hyperthermia 
and PARP inhibitors was about 36% [73]. 
Histone Deacetylase Inhibitors  
Another promising solution to the problem of 
PARP inhibitor resistance is to use histone deacetylase 
inhibitors. Acetylation and deacetylation of histones is 
an important mechanism of posttranslational 
regulation of gene expression [77]. Histone 
Acetyltransferase (HAT) enzyme catalyzes the 
reaction of adding the acetyl groups to lysine residues 
on histone complexes. On the contrary, the removal of 
the group is performed by another enzyme named 
histone deacetylase (HDAC) [78]. In addition to 
histones, HAT and HDAC also act on transcription 
factors, DNA-binding and repair proteins, molecules 
involved in signal transduction, and chaperons, thus 
regulating activities of these molecules [78]. In healthy 
cells, activities of HATs and HDACs are under 
stringent control which leads to the proper balance 
between acetylation and deacetylation of substrates 
[79]. When the balance is out of control, series of 
consequences can arise [79]. For example, it has been 
reported in several articles that improper balance 
between reaction of adding and removing the acetyl 
groups has a positive correlation with different forms 
of cancer such as prostate, breast, colorectal, and 
gastric cancers [79-82]. The main feature of 
irregularity of acetylation and deacetylation is the 
overexpression of HDACs. Treatment with HDAC 
inhibitors (HDI) sensitizes cancer cells to PARP 
inhibition. Specifically, HDI were found to enhance 
responsiveness of cells with triple negative breast 
cancers to PARP-1inhibitors [5, 83-84]. HDI-treated 
cells become responsive to PARP inhibition because of 
BRCAness effect [5]. First, HDI blocks deacetylation of 
the HSP90 heat shock protein which leads to the 
hyperacetylation and inhibition of HSP90. As a result, 
several client proteins of HSP90 including BRCA1, 
RAD52, ATR, and CHK1 cannot interact with it [5, 85]. 
The absence of interaction with HSP90 leads to the 
degradation of these proteins [5, 85]. BRCA proteins 
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are actively used in HR pathway to join DSBs in DNA 
molecule [86]. As it is expected cells have to rely on 
some alternative pathways such as NHEJ when BRCA 
genes are not functional. When treated with PARP 
inhibitors, cells become unable to repair SSBs [86]. 
SSBs are then transformed into DSBs, which are 
normally repaired by BRCA proteins [86]. As BRCA1 
is not expressed in HDI-treated cells, cells have to rely 
mostly on NHEJ which is much less accurate than HR 
and causes genome instability [86]. Eventually, due to 
excessive SSBs and build-up of DSBs, cells become 
unable to preserve the integrity of their genome and 
die by apoptosis [86]. One study showed that HDI 
treatment by vorinostat or valproic acid in DU145 and 
PC3 prostate cancer cells decreases DNA repair genes 
expression such as RAD51, CHK1, BRCA1, RAD21 
through transcription factor E2F1 [87]. In 
triple-negative breast cancer, treatment of HDI 
induces BRCAness and inhibits stemness for 
sensitizing PARP inhibitor [83-84]. Moreover, recent 
studies showed that HDI suberoylanilide hydroxamic 
acid (Vorinostat, SAHA) and PARPi, PJ34, 
synergistically induce cell death in anaplastic thyroid 
carcinoma and leukemia cells [88-89].  
Targeting Heat Shock Protein 90 and BRCA1 
Stabilization 
To inactivate HSP90 protein is also an exciting 
method to solve the issue of PARP inhibitor resistance 
and it has been undergoing clinical trials [22, 90]. 
HSP90 functions as a chaperone molecule, which 
assistants in folding of different proteins such as 
epidermal growth factor receptors (EGFR), Protein 
Kinase B (AKT), MET, and Raf-1 kinase for acquiring 
functional 3D structures [91]. Furthermore, it is 
observed that the HSP90 chaperone stabilizes many 
tumor suppressors and proto-oncogenic proteins 
derived from the mutated genes, thus preventing 
their ubiquitin-proteasome degradation [89]. Such 
chaperone-mediated stabilization of oncogenic 
proteins is generally correlated with resistance to 
chemotherapy treatment [7]. For example, Curtin and 
colleagues detected a high level of expression of a 
mutated BRCA1 and HSP90 as well as 53BP1 loss in a 
cisplatin-resistant MDA-MB-436 cancer cell line [7]. 
DNA repair focus is usually the first event 
observed during DNA repair through HR pathway 
[92]. One of the active participants of DNA repair via 
HR mechanism is BRCA1 [85]. However, the exact 
mechanism underlying how BRCA1 mediates HR is 
still under the investigation [93]. Nevertheless, 
researchers found that BRCA1 acts as a mediator and 
co-factor of this process by binding to CtIP to produce 
resection at 5' broken ends [93]. Clearly mutated or 
truncated BRCA1 cannot perform this function 
properly [5]. Cancer cells usually circumvent this 
problem by activating the HSP90 that stabilizes 
BRCA1 protein to form a complex with the Partner 
and Localizer of PALB2-BRCA2-RAD51 recombinase 
(PALB2-BRCA2-RAD51) at the site of DNA repair 
focus [5]. Consequently, CtIP has unrestricted access 
to DNA breaks with the subsequent process of the 
strand invasion and DNA repair during HR pathway 
[1]. The key role of the HSP90 in the prevention of 
ubiquitin-proteasome degradation of many 
oncogenes has attracted a great attention in the field 
of chemotherapy [92]. Currently different inhibitors of 
the HSP90 are undergoing preclinical studies and 
clinical trials such as isoxazole derivative 
VER-52296/NVP-AUY922 and purine derivative 
BIIB021 [94-96]. Recent study suggests that free 
XRCC1 is a substrate of HSP90 and associates with 
DNA polymerase β complex for stabilization to 
determine the DNA repair construct and BER fate 
[97]. Thus, scientists propose that targeting both 
PARP1 and HSP90 would activate NHEJ pathway 
that usually causes genomic instability and cell death 
[98]. A more recent pre-clinical study showed that 
combination of PARPi Olaparib and HSP90 inhibitor, 
AT13387 in patient derived xenograft mouse model of 
ovarian cancer showed synergistic efficiency in 
disruption of tumor growth in 
BRCA1-mutated/PARPi-resistant model and phase I 
clinical trial of drug combination has been on 
designing [99]. While a large number of proteins are 
HSP90 clients and HSP90 inhibitors may have 
off-target effect on crosstalk signaling pathways of 
client proteins, in personalized treatment, it should be 
cautious to use combined HSP90 inhibitors and 
PARPi.  
Inhibition of Cyclin-Dependent Kinase 1  
Cyclin-dependent kinase 1 (CDK1) (another 
name is CDC2) is a Ser/Thr kinase [100]. This protein 
is often called M-phase promoting factor (MPF) and 
functions in G1/S and G2/M phases of cell cycle 
[100]. To review, cells can progress through the 
phases of cell cycle due to periodic production and 
degradation of cyclins, which function as partners of 
CDK1 [100]. For example, production and 
maintenance of cyclin A2 is critical to prevent the 
re-replication of DNA in S phase [101]. One main 
function of CDK1 is to participate in HR repair 
pathway [102]. Specifically, this kinase 
phosphorylates BRCA1 to promote the proper 
formation of DNA repair foci [102]. This focus also 
includes a variety of proteins and regulators such as 
abraxas-RAP80 complex, PALB2, BRCA2, and RAD51 
[103, 104]. In addition, CDK1 enhances the production 
of ATP in mitochondria by phosphorylating the 
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mitochondrial complex I in the electron transport 
chain [105]. The high ATP production allows cells to 
meet the elevated energy consumption in order to 
repair DNA and avoid apoptosis [105]. 
A cell usually controls the activity of CDK1 
levels by p53 or phosphorylation by CDK-activating 
kinase (CAK) [100,106,107]. One promising drug 
RO-3306 inhibits CDK1 10-fold more selectively than 
with CDK2 and 50-fold more selectively than with 
CDK4 [100, 108]. It is attractive to block CDK1 activity 
to enhance the efficiency of PARP inhibition therapy. 
One study showed that CDK1 knockdown by 
inducible shRNA sensitizes PARPi AG14361 
inhibition by elevation of chromosome aberrations 
and cell death [109]. In mouse model of lung cancer 
induced by Kras/Trp53 mutations, combined Cdk1 
and Parp inhibition decreased tumor size and 
increased survival [109]. 
Inhibition of BARD1 disrupts BRCA1 
To promote export of BRCA1 to the cytoplasm 
can be an interesting method to overcome resistance 
to PARP inhibitors [110]. Many proteins, RNAs, and 
other regulatory molecules cross the nuclear 
membrane by active transport using importin or 
exportin receptors [111]. Nuclear export usually relies 
on one of the seven well studied exportin receptors, 
specifically Exportin 1 or Chromosome Region 
Maintenance 1 protein (XPO/CRM1) receptor [112]. 
For example, many regulatory RNA molecules and 
over 200 different proteins like Foxo and BRCA1 can 
pass through the nuclear membrane with the 
assistance of XPO/CRM1 exportins [112-113]. At the 
molecular level, Ran GTPase should recognize the 
specific Nuclear Export Signal Sequence (NES) on 
these proteins before binding to XPO/CRM1 and 
forming a ternary complex, which then should be 
exported to the cytoplasm, where Ran GTP is 
hydrolyzed back to Ran GDP releasing the cargo 
[112]. 
The appropriate localization of BRCA1 is critical 
for cellular processes because it plays a different role 
depending on its cellular localization [111]. In 
particular, BRCA1 participates in the HR process 
inside the nucleus, promotes microtubule nucleation, 
and prevents centrosome duplication by binding to 
the BARD1 [111]. Researchers concluded that BARD1 
stabilizes and confines BRCA1 to the nucleus [114]. 
BARD1 could bind to the N -terminal RING domain 
as well as the NES of BRCA1 [115]. Interestingly, 
BRCA1-BARD1 interaction usually prevents the 
transport of BRCA1 by Ran GTPase and XPO/CRM1 
pathway [113, 116]. Specifically, scientists highlight 
that about 75% of nuclear BRCA1 makes stable 
complexes with BARD1 [115]. Furthermore, 
researchers showed that the depletion of nuclear 
BARD1 increases the export of BRCA1 from the 
nucleus [115, 117]. Overall, it seems both attractive 
and promising to block BARD1 in combination with 
the PARP inhibition therapy. For instance, recent 
studies showed that in colon cancer, BARD1 splice 
variant, BARD1β which has deletions of RING 
domain, can disrupt BRCA1 E3 ligase activity, and 
prevent BRCA1 nuclear localization [118]. Most 
importantly, overexpression of BARD1β, a 
dominate-negative form of BARD1, abolishes HR and 
RAD51 foci and can sensitize colon cancer cells to 
PARPi [118]. Thus targeting BARD1 can be an 
alternative approach to interfere BRCA1 to overcome 
PARPi resistance.  
p53 stabilizer reverses PARPi drug resistance  
It has been shown that p53 is also a regulator of 
cytosol-nucleus translocation of BRCA1 possibly 
affecting BRCA1 mediated DNA repair. p53 can 
interact with BRCA1 to decrease nuclear BRCA1 by 
nuclear export [119] thereby possibly inhibiting 
nuclear BRCA1 mediated PARPi drug resistance. p53 
mediated shuttling of BRCA1 increases cytotoxicity 
and sensitization to DNA damage by radiation is not 
through p53 mediated transcriptional activity but 
only dependents on their interactions [119]. It has 
been shown that cytosolic BRCA1 can enhance 
apoptosis and can cause the loss of DNA DSB repair 
even though the two processes are not associated 
[120]. p53 stabilization agent such as Nutlin-3, which 
inhibits MDM2 E3 ligase of ubiquitination and 
degradation of p53, has been widely used for 
enhancing p53 signaling [121]. Thus p53 stabilizer can 
be applied for overcoming PARPi resistance. Indeed it 
has been shown that Nutlin-3 increased breast cancer 
cells to PARP inhibitor IQD with a decrease of DSB 
HR [121]. Moreover, another study in wild type of p53 
expressing cells of multiple myeloma showed that p53 
stabilizer Nutlin-3a together with PARPi Olaparib 
enhanced apoptosis and PARPi sensitivity but not in 
p53 mutant cells [122]. Thus combinational treatment 
of p53 stabilizer and PARPi can be a novel avenue to 
enhance chemotherapy by reverse PARPi resistance 
[122]. While p53 regulators are abundant, targeting 
BRCA1 through p53 pathway regulators might 
generate many novel avenues to inhibition of PARPi 
drug resistance. Although there might be crosstalk 
signaling which can interfere the p53/BRCA1 
feedback, stabilizing p53 to target DSB repair by 
BRCA1 is still promising in cancer treatment 
especially in precision therapy.  
Conclusion and Perspectives 
It has been widely believed that PARP inhibitors 
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are promising agents for cancer treatment. They act by 
inhibiting SSBs repair pathway, which is normally 
initiated and mediated by PARP enzymes. Many 
clinical trials show that PARP inhibitors are 
promising in treatment of cancers. However, in some 
instances patients do not respond effectively to this 
therapy probably because of tolerance of PARP 
inhibitors. Particularly, tumor cells could show 
tolerance to this therapy by increasing efflux of the 
drugs through Pgp, overexpressing PARP1, reducing 
inhibitors’ affinity for PARP1, restoring HR repair 
pathway, and suppressing NHEJ. In this review, we 
discussed several mechanisms underlying resistance 
as well as some promising solutions to overcome it. 
The methods of overcoming the resistance are based 
on the direct or indirect inactivation of BRCA and 
other HR proteins. This inactivation should end up in 
accumulation of DSBs leading to apoptosis. It has 
been speculated by several researchers that these 
methods should sensitize resistant cancer cells to 
PARP inhibition (Figure 1). When these methods are 
applied in combination with PARP inhibitors, their 
action can be synergized leading to a greater efficacy 
than either treatment. For example, one recent study 
compared the differential combinational effect to 
overcome PARPi resistance. The authors found that 
two drugs which knowingly inhibit PARPi, combined 
with HDAC inhibitor can efficiently inhibit drug 
resistance of PARPi [123]. First the authors found that 
HDAC inhibitor Vorinostat increases the sensitivity of 
cancer cells to PARPi ABT-888 in both cell lines and 
xenograft model by elevation of eIF2α 
phosphorylation but not expression levels of BRCA1, 
RAD51 or 53BP1[123]. Then the authors found the 
anti-metabolite drug 6-thioguanine (6-TG) which can 
inhibit proliferation in BRCA deficient cells [124] 
through sensitizing PARPi, can further increase 
phosphorylated eIF2α to induce cell death [123]. In 
summary, next generation PARPi of non-substrate of 
ABC drug transporters based cocktail therapy may 
provide a promising treatment avenue in clinics. 
However, drug-drug interactions must be 
investigated when using combinational therapy. The 
next stage of the research in this field is to examine the 
combined efficiency of these methods in overcoming 
PARP inhibitor resistance in clinical trials. 
 
 
 
Figure 1. Summary of Potential Avenues to Overcome Resistance to PARPi in Chemotherapy 
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